Prescrire Int. 1998 Dec;7(38):174-6.
(1) The action of benazepril on the progression of renal failure in non diabetic patients has been assessed in a comparative placebo-controlled trial involving nearly 600 patients, most of whom were hypertensive. (2) This trial showed a statistically significant slowing of renal failure on benazepril, but the possibility of bias casts doubts on this conclusion; moreover, excess deaths occurred in the benazepril group. (3) Currently, the slowing of the progression of renal failure is not a valid basis for choosing between angiotensin-converting-enzyme inhibitors for non diabetic hypertensive patients with renal failure.
（1）在一项涉及近600名患者（其中大多数为高血压患者）的对照安慰剂试验中，评估了贝那普利对非糖尿病患者肾衰竭进展的作用。（2）该试验显示，服用贝那普利后肾衰竭在统计学上有显著减缓，但存在偏倚的可能性使这一结论受到质疑；此外，贝那普利组出现了额外死亡病例。（3）目前，对于患有肾衰竭的非糖尿病高血压患者，肾衰竭进展减缓并不是在血管紧张素转换酶抑制剂之间进行选择的有效依据。
